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Abstract
Background: Since December 2009, Me ´decins Sans Frontie `res has diagnosed and treated patients with visceral
leishmaniasis (VL) in Tabarak Allah Hospital, eastern Gedaref State, one of the main endemic foci of VL in Sudan. A survey
was conducted to estimate the VL incidence in villages around Tabarak Allah.
Methods: Between the 5
th of May and the 17
th of June 2011, we conducted an exhaustive door-to-door survey in 45 villages
of Al-Gureisha locality. Deaths were investigated by verbal autopsies. All individuals with (i) fever of at least two weeks, (ii)
VL diagnosed and treated in the previous year, and (iii) clinical suspicion of post-kala-azar dermal leishmaniasis (PKDL) were
referred to medical teams for case ascertainment. A new case of VL was a clinical suspect with a positive rk39 rapid test or
direct agglutination test (DAT).
Results: In the 45 villages screened, 17,702 households were interviewed, for a population of 94,369 inhabitants. The crude
mortality rate over the mean recall period of 409 days was 0.13/10’000 people per day. VL was a possible or probable cause
for 19% of all deaths. The VL-specific mortality rate was estimated at 0.9/1000 per year. The medical teams examined 551
individuals referred for a history of fever of at least two weeks. Out of these, 16 were diagnosed with primary VL. The overall
incidence of VL over the past year was 7.0/1000 persons per year, or 7.9/1000 per year when deaths possibly or probably
due to VL were included. Overall, 12.5% (11,943/95,609) of the population reported a past VL treatment episode.
Discussion and Conclusion: VL represents a significant health burden in eastern Gedaref State. Active VL case detection had
a very low yield in this specific setting with adequate access to care and may not be the priority intervention to enhance
control in similar contexts.
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Introduction
Visceral leishmaniasis (VL), also called kala-azar, is a parasitic
disease caused by members of the Leishmania donovani complex (L.
donovani and L. infantum) and transmitted by the female phlebotomine
sand flies of the genera Phlebotomus (Old World) and Lutzomyia (New
World). It mainly affects areas in South Asia (India, Bangladesh, and
Nepal)andEasternAfrica,whereSudanisthemostaffectedcountry,
followed by Ethiopia, Kenya, Somalia and Uganda. In Sudan, the
causative agent is L. donovani, transmitted by the Ph. orientalis.
Gedaref State is the main endemic area of VL in Sudan. Passive
detection figures from 1996 to 1999 have shown a mean yearly
incidence between 6.6 and 8.4 VL cases per 1000 persons, with a
large variation between villages (from 0 to 60 cases per 1000
persons per year) [1,2]. Villages with high incidence are clustered
along two rivers (Atbarah and Rahad), in areas of low altitude and
high rainfall. Leishmanin skin testing, a marker of past exposure to
the disease, has been shown to be positive in 21.6% of the
population of the Atbarah area [3].
Many individuals infected by L. donovani have subclinical
infection, while others develop clinical VL, a devastating illness
that is usually fatal when left untreated. In Sudan, clinical signs
develop gradually 2 weeks to 1 year after infection (in most cases
after 2 to 4 months). Typical features are persistent fever,
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azar dermal leishmaniasis (PKDL) is a skin rash appearing after
VL treatment, affecting up to 50% of treated cases in Sudan [5].
PKDL usually appears within 6 months after apparent cure and
can last for months or years. Leishmania parasites can be found in
smears of the skin lesions, and PKDL lesions are suspected to be
an important parasite reservoir for human-to-human transmission.
In Sudan, most lesions heal spontaneously. If not, PKDL
treatment is challenging [6].
Some vector-control strategies such as indoor residual spraying
have been shown to reduce the density of sand fly vectors in the
Indian subcontinent [7], where the vector Ph. argentipes exhibits a
behaviour different from the Sudanese vector. In Africa, bednet
use has been shown to potentially reduce VL incidence [8]. Also,
strategies to promote early detection and treatment have been
shown to reduce case-fatality rates of VL in Brazil, where zoonotic
VL is caused by L. infantum (syn. L. chagasi) [9]. Furthermore, early
detection and treatment of anthroponotic VL patients is also
believed to lower transmission through the reduction of the human
reservoir [10]. This is supported by one pilot study that achieved
good results using a combination of active detection, treatment
and indoor residual spraying after a local outbreak of VL in one
village located in the Bihar State of India [11]. However, although
recommended, this strategy has never been formally evaluated in
L. donovani endemic areas and is rarely implemented.
Since December 2009, Me ´decins Sans Frontie `res (MSF) has
been diagnosing and treating patients presenting at Tabarak Allah
Hospital, located in Al-Gureisha locality of the the Atbarah focus.
MSF intended to conduct a cluster-randomized trial to evaluate
the impact of an active VL and PKDL case detection strategy on
the incidence of clinical VL. For the appropriate planning of this
trial, a baseline survey was conducted in eligible villages around
Tabarak Allah Hospital. The main objective of this survey was to
estimate the incidence rate of VL over a one-year period at the
village level. Additionally, we also aimed at retrospectively
estimating the crude and VL-specific mortality rates, the
proportion of VL cases missed by the passive case detection
system in place, the proportion of the population treated for VL in
the past, and the proportion of PKDL among patients previously
treated for VL.
Methods
Ethics Statement
Ethical clearance was granted from the Sudanese National
Ministry of Health’s Research Ethics Review Committee. Written
authorization to conduct the study was obtained from the Gedaref
Ministry of Health and each head of village. Each head of
household provided oral informed consent to the collection of
demographical data, history of VL treatment, skin rash after
treatment, and presence of fever of at least two weeks among
household members. A referral form was given for each individual
presenting with fever of more than two weeks, with suspicion of
PKDL or having been treated for VL in the last year. The
information included in these forms was not identifying and
individuals were free to reach or not the medical team for clinical
investigation. An additional oral consent was obtained from
clinical suspects before testing for VL. The choice of oral consent
was made because of the low literacy rate in the study area and the
unlikelihood to easily find an impartial literate witness for each
household. The Sudanese National Ministry of Health’s Research
Ethics Review Committee expressly approved the method of oral
consent without use of a witness or written record of oral consent.
Between the 5
th of May and the 17
th of June 2011, we
conducted an exhaustive door to door survey in the 45 villages of
Al-Gureisha locality, covering a population of about 85,000
inhabitants. The survey villages were grouped into four geograph-
ical areas. Each area was surveyed by four field teams and one
medical team.
Demographic information (age, sex, household composition on
the day of survey and one year prior, number of births, deaths and
movements within the past year) was collected by the field teams in
each household. A household was defined as all people living
together under the responsibility of one head of household and
eating regularly together. For each household member, the history
of VL treatment and possible subsequent PKDL was also
recorded. The number and the causes of any death occurring in
the past year were investigated in order to identify deaths possibly
attributable to VL. Verbal autopsies were conducted for all
reported deaths except for neonatal, delivery-related, and
accidental deaths, as these were unlikely to be related to VL.
Maternal deaths not directly related to delivery were investigated,
as VL during pregnancy is known to be associated with increased
treatment toxicity and mortality [12,13].
Individuals with fever of at least two weeks duration, individuals
diagnosed and treated for VL during the past year, and clinical
suspects of either PKDL or VL relapse (independently of the time
elapsed since treatment) were referred to the medical teams for
clinical examination and case ascertainment. New clinical VL
suspects (defined as fever for at least two weeks with at least one of
the following: splenomegaly, lymphadenopathies or history of
weight loss) were tested with an rK39 antigen-based rapid test
(DiaMed IT-Leish) [14] and, if negative, with the direct
agglutination test (DAT) [15,16] for VL confirmation. A new
VL case was defined as a clinical suspect who was confirmed either
by the rK39 or the DAT. New VL cases, suspected VL relapses,
and moderate and severe PKDL cases were referred to Tabarak
Allah Hospital. Because of the self-healing nature of PKDL in
Sudan and the potential toxicity of the recommended SSG
treatment, mild PKDL cases were not offered SSG treatment [6]
and therefore were not referred to Tabarak Allah Hospital.
Author Summary
Visceral leishmaniasis (VL) is a life-threatening parasitic
disease, transmitted by a sandfly. A survey was conducted
to estimate the VL incidence in 45 villages located in the
eastern part of Gedaref State, the main endemic focus of
VL in Sudan. Between the 5
th of May and the 17
th of June
2011, we interviewed 17,702 households for a population
of 94,369.
Sixteen individuals were diagnosed with primary VL
through active case-detection, and 725 reported VL
treatment over the past year. The overall incidence rate
of VL over the past year was 7.0/1000 persons per year.
The crude mortality rate over the mean recall period of 409
days was 0.13/10’000 persons per day. VL was a possible or
probable cause for 19% of all deaths. Taking also into
account the VL-specific mortality of 0.9/1000 per year, the
incidence was estimated at 7.9/1000 per year. Overall,
12.5% of the population reported having been treated for
VL in the past.
VL is a major public health issue in Gedaref. Active VL case
detection had a very low yield in a context of adequate
access to care. Such strategy seems redundant if patients
already have access to care.
Burden of Visceral Leishmaniasis, Eastern Gedaref
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population was exhaustively screened. We calculated a sample
size of 266 deaths to estimate a proportion of deaths due to VL of
30% with a 5% precision (alpha 0.05). Based on an expected total
number of deaths around 1500 (corresponding to an annual
mortality rate of 0.5/10’000 persons per day), we planned to
investigate the cause of every fifth death through verbal autopsy,
using a systematic sampling procedure. All deaths were recorded
consecutively on a tally sheet, with the death to be investigated
pre-highlighted. As the data collected during the first three weeks
of the survey showed a number of deaths much lower than
expected, we later conducted verbal autopsies for every reported
death. The analysis of the causes of death was weighted
accordingly.
All verbal autopsies were reviewed independently by two
clinicians experienced in VL and fluent in Arabic. In case of
disagreement, the files were reviewed by a third expert clinician,
with the help of a translator, and his verdict was final. Death was
considered possibly due to VL if the respondent mentioned fever
of at least two weeks duration and either one of the following:
enlarged lymph nodes, a visible mass in the left upper part of the
abdomen (spleen side), or weight loss, during the final illness of the
deceased. Death was considered as probably due to VL if it
occurred during treatment for VL (clearly mentioned by the
relatives of the deceased) in a treatment facility offering reliable
VL diagnosis (i.e. rk39 rapid test, DAT or microscopic examina-
tion of lymph node aspirate with quality control in place). If a
death was reported to have occurred in another treatment facility
during VL treatment, it was considered as possibly due to VL.
The event chosen to define the start of the recall period
(covering the past year) was the presidential elections in Sudan,
which occurred on the 10
th and 11
th of April 2010. The average
recall period (referred hereafter as the ‘‘the past year’’) was
therefore 409 days. The end of the sesame harvest (end of October
2010) was used to define a 6-month recall period. VL incidence
rate over the period was calculated by summing the new VL cases
detected during the survey, the VL cases and the deaths possibly/
probably due to VL reported over the recall period, divided by the
mid-year population.
All documents were translated in Arabic and back-translated
into English, and were subjected to pilot testing with subsequent
update before the start of the survey. Data were entered in the
EpiData software (EpiData, Odense, Denmark) by four data entry
clerks. Data were analysed using the Stata 11 software (Stata
Corporation, College Station, Texas, USA). Description of
geographical information was performed using the QuantumGIS
software, version 1.7.0. The coordinates of the Atbarah River were
obtained by manually drawing along the river in Google Earth.
Results
A total of forty-five villages were screened, corresponding to
17,965 households, 17,702 (98.5%) of which gave verbal consent
to participate. The mid-year population was 94,369 inhabitants.
The median household size at the time of the survey was 5 persons
(interquartile range (IQR) 3 to 7 persons). The male/female sex
ratio was 1.08. The median age was 15 years (IQR 7 to 30 years).
The median population size by village was 1241 inhabitants (IQR
692 to 3113) at the time of the survey.
Overall, 12.5% (11,943/95,609) of the population reported
having been treated for VL in the past, varying between 1.8% and
34.7% across villages. The medical teams assessed 725 individuals
reporting VL treatment in the past year. Out of them, 125 (24%)
mentioned a rash occurring within a median of 2 months after VL
treatment (IQR 1 to 4 months) and lasting for a median of 3
months (IQR 1 to 10 months). Overall, PKDL was diagnosed in
260 cases (123 treated within the past year, 137 treated more than
one year ago), corresponding to 0.3% of the survey population.
The prevalence of PKDL cases ranged from 0 to 1.5% across
villages. Most of the observed PKDL rashes were mild (81.5%) and
none required treatment. In addition, the medical teams referred
40 patients for suspected VL relapse. Microscopic examination of
lymph node aspirate was negative in 38 individuals and positive in
2 patients therefore diagnosed with VL relapse and treated.
The medical teams examined 551 subjects not previously
treated for VL (Figure 1). Of these, 239 qualified as new clinical
VL suspects, while the remaining 312 did not meet the case
definition. Sixteen patients were ultimately diagnosed with
primary VL (12 by rK39 rapid test and 4 by DAT), 85% of
whom had actually sought care previously. Compared to the 725
cases treated in the past year, the active case detection therefore
allowed to diagnose 16 (2%) additional of new cases. The age and
sex distribution of the 741 VL cases newly diagnosed or treated in
the past year is shown in Table 1. Males represented 54% of the
cases, and 59.5% of the cases were aged from 5 to 14 years. The
overall incidence rate of VL cases over the mean recall period of
409 days was 7.0/1000 persons per year. VL incidence rates by
village varied between 0 and 23.0/1000 persons per year
(Figure 2).
Five hundred and six deaths were reported, resulting in a crude
mortality rate (CMR) of 0.13/10,000 persons per day. At the
village level, the CMR varied between 0.02 and 0.30/10,000 per
day, with a median of 0.14/10,000 per day. Accidental deaths
represented 19.6% of all deaths, while neonatal and delivery-
related deaths represented 14.8% and 1.8%, respectively. The
remaining deaths were investigated by 171 verbal autopsies,
corresponding to 299 deaths (32 sampled in the initial period of
the survey given a weight of five, plus 139 for the remaining time
of the survey). Taking into account the weighting, VL was a
possible or probable cause of death in respectively 3.7% and
26.1% of verbal autopsies, or 2.4 and 16.6% when extrapolated to
the total number of deaths. Other main causes of death were acute
febrile illnesses (17.1%) and death related to chronic non-
communicable diseases, mainly cardiovascular disease and di-
abetes (9.6%). Among the deaths probably/possibly due to VL
(weighted n=89), 45% occurred at home, 89% had received a
medical treatment, and 53% had a clear history of VL treatment.
The VL-specific mortality rate was 0.9/1000 persons per year.
Taking into account these deaths possibly or probably due to VL,
the overall incidence rate of VL cases over the recall period would
reach 7.9/1000 per year.
Discussion
In eastern Gedaref State, one out of 127 inhabitants was
affected by VL over the past year. These incidence rates were
lower than figures previously reported from the same region [1].
Still, a large proportion of the population (12.5%) has been
affected by clinical VL in the past, reaching over one third in some
villages. Also, one fifth of all deaths in the previous year may have
been due to VL. However, there was no clear correlation between
VL incidence and crude mortality rates at village level, which were
overall lower than the reported average in Sudan [17,18]. Still, VL
represents an important burden in these communities, even
between peaks of high incidence that occur approximately every
six to ten years in Sudan [2,18].
Interestingly, although gender is usually mentioned as a risk
factor for VL [19], our data did not show a strong male
Burden of Visceral Leishmaniasis, Eastern Gedaref
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Project data from Tabarak Allah Hospital report 55% males
among patients treated for VL, which is lower than figures
reported from other treatment centres of Gedaref in the past
[20,21]. It is unclear whether this difference reflects differential
access issues, changing epidemiology over time, or focal differences
in transmission patterns. By contrast, age was clearly associated
with VL: almost 60% of the cases were aged between five and 14
years, while this age group only represented 30% of the general
population.
Up to one quarter of patients treated for VL within the past year
reported some skin change consistent with PKDL, appearing
within a median of two months after treatment and lasting for a
median of three months. This is lower than reported in previous
Figure 1. Flowchart of individuals assessed for fever of at least 2 weeks duration, eastern Gedaref State, Sudan, May-June 2011.
* Positive rK39 test in PKDL suspect, never treated for VL in the past. DAT: Direct Agglutination Test.
doi:10.1371/journal.pntd.0001872.g001
Table 1. Age and sex distribution of VL cases in the past year (725 previously treated cases and 16 new cases) and of the general
population, eastern Gedaref State, Sudan, May-June 2011.
VL cases General population
Male Female Total Male Female Total*
Age group n (%) n (%) n (%) n (%) n (%) n (%)
- 0 to 4 years 67 (16.6) 63 (18.7) 130 (17.5) 8620 (17.4) 8017 (17.4) 16667 (17.4)
- 5 to 14 years 250 (61.9) 191 (56.7) 441 (59.5) 14613 (29.5) 14013 (30.5) 28644 (30.0)
- 15 and above 82 (20.3) 78 (23.1) 160 (21.6) 26254 (53.0) 23919 (52.0) 50220 (52.5)
- Missing 5 (1.2) 5 (1.5) 10 (1.3) 34 (0.1) 40 (0.1) 78 (0.1)
Total 404 (54.5) 337 (45.5) 741 (100.0) 49521 (51.8) 45989 (48.1) 95609 (100.0)
*Missing sex in general population: 99 (30 aged 0 to 4 years old, 18 aged 5 to 14 years old, 47 aged 15 and above, 4 with missing age).
doi:10.1371/journal.pntd.0001872.t001
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[22,23]. However, we only reported the proportion of PKDL
among patients treated within the past year. Some patients were
therefore likely to develop PKDL within the year after completion
of the survey. Also, patients may not have reported mild and short-
lasting PKDL. Although most PKDL cases are mild, they could
still represent a reservoir of parasites, as L. donovani parasites can be
detected in skin lesions [24]. None of the PKDL treatment
currently available appears appropriate to treat mild cases, either
because of toxicity (antimonials, conventional amphotericin B),
teratogenicity (miltefosine) or cost (liposomal amphotericin B). As
long as there is no definite evidence for the role of PKDL cases in
the transmission chain, it is difficult to advocate for the
development of better and simpler treatments for this condition.
Active VL case detection allowed us to detect an additional two
percent of cases (n=16/725). This appears as a very low yield for
such a labour-intensive and costly operation. The survey was
conducted at a time of the year when the number of new cases
recorded at Tabarak Allah hospital is usually low. Thus, our
results confirm that the incidence of clinical VL is low in May and
June, and that this is not related to restricted access or use of health
services. Active case detection may have detected more cases if it
had been done from September to November, just after the rainy
season, when incidence is believed to be higher and when many
clinical cases have not yet sought medical care. However, the
2010–2011 Tabarak Allah hospital data neither show a clear
seasonal trend, nor a large seasonal difference in delays for seeking
care. Adequate access to care was confirmed by the short duration
of symptoms reported by most VL cases on admission to Tabarak
Allah Hospital (source: MSF project data). Also, most of the 16
new VL cases detected by the survey teams had actually previously
sought care at health centres but were not adequately diagnosed
with VL during that consultation. Our results show that when
good-quality services are made accessible to a population that is
well sensitized, active case detection might not be relevant. Based
on our results, MSF decided not to proceed with the initially
planned trial on active case detection, and not to recommend
active case detection as a control strategy in the area.
A recent mathematical transmission model based on south
Asian data suggested that VL treatment only had almost no effect
on the overall intensity of transmission, which was mainly
attributed to asymptomatically infected hosts [22,23,25]. These
results cannot be extrapolated directly to Sudan where the VL
epidemiology is very different, especially regarding the asymp-
tomatic to symptomatic ratio that is much lower than in India
[26]. Nevertheless it would be useful to adapt this model with
Sudanese data, in order to guide efforts for VL control in the
future.
The main limitation of our survey was the length of the recall
period (over one year). Memory inaccuracies may have led to an
overestimation of VL incidence, since VL cases that occurred
more than one year prior the survey may have been reported as
Figure 2. Incidence of VL over past year, eastern Gedaref State, Sudan, May-June 2011. * The size and the colour of the circles are
proportionate to VL incidence.
doi:10.1371/journal.pntd.0001872.g002
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the past year may have been erroneously counted as new VL cases.
Seasonal workers who left the area and developed VL later and
elsewhere in Sudan were not included in the incidence results.
These potential biases acted in opposite directions, which may
have mitigated their impact on the estimated incidence of VL.
Moreover, these biases being similar across villages, the relative
differences in VL incidence still identify the villages most affected
by VL in the study area.
The one out of five sampling of deaths submitted to verbal
autopsy in the initial period of the survey may have caused some
selection of the deaths investigated, which could have led to an
overestimation of the proportion of deaths attributed to VL.
However, the characteristics of deaths and the proportion
attributable to VL were similar between the two periods,
indicating no such phenomenon. We cannot exclude that some
of the deaths attributed to VL may have been due to another
disease causing similar symptoms, such as tuberculosis, advanced
HIV infection, or cancer.
Conclusions
VL represents a significant health burden in the villages of
eastern Gedaref State. The disease was among the major causes of
death in the area. Active VL case detection through door-to door
screening did not prove to be an efficient way to diagnose new VL
cases likely due to current good access to VL care and relatively
low prevalence of cases because the survey took place during a
low-transmission period.
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